Re-irradiation for Metastatic Brain Tumors with Whole-brain Radiotherapy
Open Access
- 9 February 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 42 (4) , 264-269
Abstract
To determine whether second whole-brain irradiation is beneficial for patients previously treated with whole-brain irradiation. A retrospective analysis was done for 31 patients with brain metastases who had undergone re-irradiation. Initial whole-brain irradiation was performed with 30 Gy/10 fractions for 87% of these patients. Whole-brain re-irradiation was performed with 30 Gy/10 fractions for 42% of these patients (3–40 Gy/1–20 fractions). Three patients underwent a third whole-brain irradiation. The median interval between the initial irradiation and re-irradiation was 10 months (range: 2–69 months). The median survival time after re-irradiation was 4 months (range: 1–21 months). The symptomatic improvement rate after re-irradiation was 68%, and the partial and complete tumor response rate was 55%. Fifty-two percent of the patients developed Grade 1 acute reactions. On magnetic resonance imaging, brain atrophy was observed in 36% of these patients after the initial irradiation and 74% after re-irradiation. Grade ≥2 encephalopathy or cognitive disturbance was observed in 10 patients (32%) after re-irradiation. Based on univariate analysis, significant factors related to survival after re-irradiation were the location of the primary cancer (P = 0.003) and the Karnofsky performance status at the time of re-irradiation (P = 0.008). A Karnofsky performance status ≥70 was significant based on multivariate analysis (P = 0.050). Whole-brain re-irradiation for brain metastases placed only a slight burden on patients and was effective for symptomatic improvement. However, their remaining survival time was limited and the incidence of cognitive disturbance was rather high.Keywords
This publication has 17 references indexed in Scilit:
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Value of Whole Brain Re-irradiation for Brain Metastases — Single Centre ExperienceClinical Oncology, 2007
- Radiosurgery for Metastatic Brain Tumors2007
- The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Radiotherapeutic management of brain metastases: A systematic review and meta-analysisCancer Treatment Reviews, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- Analysis of outcome in patients reirradiated for brain metastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Epidemiology of brain tumorsNeurology, 1985